RE:Great news on cancer, anyone awake out there? Honestly investors are just desensitized to IMV news release at this point. The results are very interesting though particularly this section:
As of the data cut-off date for the presentation at SITC, 18 pre-treatment samples from patients enrolled in the SPiReL study were available for biomarker analysis. Thirty nine percent (7/18) of subjects demonstrated a positive pre-treatment tumor PD-L1 expression. Key findings for this population include:
- 100% of subjects with Disease Control Rate (DCR) defined as Stable Disease (SD) or Complete or Partial Response (CR or PR)
- 86% (6/7) of subjects with Objective Response Rate (ORR) (3 CR, and 3 PR)
The PD-L1 pathway regulates T-cell responses allowing tumors to evade detection by the immune system. PD-L1 expression has been extensively studied in relation to the prognosis of various cancers and is approved in multiple tumor types as a predictive biomarker for treatment with checkpoint inhibitors targeting the PD-1/PD-L1 pathway. In DLBCL, PD-L1 has been shown to be expressed in 26% to 75% of patients and is generally thought to be associated with a poor prognosis and shorter survival 1,2 .
Checkpoint inhibitors such as Keytruda ® and Opdivo ® are not approved in DLBCL and have demonstrated limited activity including in PD-L1 positive patients. 1,3"
It's interesing that Keytruda has very limited action on PD-L1 pos patients but soon as you add DPX to the mix its a near 100% ORR. So what mechanism exactly here is creating this insane synergy. Anything that bumps up Keytruda effectiveness is def a take over target for Merck we know this much...
QM45 wrote: 86% response rate, biomarker that works. We are cancer company once again!!!